Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry…
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known…
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase priceNEW YORK…
Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive…
This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for…
April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group,…
DELRAY BEACH, Fla., Feb. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Digital X-ray Market is estimated to reach USD…
WINSTON-SALEM, N.C., Feb. 2, 2026 /PRNewswire/ -- mPATH® Health, a digital health company focused on improving cancer screening through evidence-based technology,…
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well…